Vor Biopharma (VOR) EPS (Weighted Average and Diluted) (2021 - 2026)
Vor Biopharma (VOR) reported EPS (Weighted Average and Diluted) of -$5.11 for Q1 2026, up 1.92% year-over-year from -$5.01 in Q1 2025, and down 101.66% on a QoQ basis from $307.61 in Q4 2025.
Vor Biopharma (VOR) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$5.11 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 1.92% year-over-year to -$5.11 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168.31 (up 849.71% YoY) and the FY2025 annual result came in at -$70.5, down 107.17% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$5.11 in Q1 2026 per VOR's latest filing, from $307.61 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $307.61 in Q4 2025 and bottomed at -$121.63 in Q3 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.58 (2022), against an average of $8.31.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 3603.53% in 2025, while the deepest fall reached 2963.41% in 2025.
- Tracing VOR's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.52 in 2022, then advanced by 26.92% to -$0.38 in 2023, then tumbled by 2210.53% to -$8.78 in 2024, then surged by 3603.53% to $307.61 in 2025, then slumped by 101.66% to -$5.11 in 2026.
- Per Business Quant, the three latest VOR EPS (Weighted Average and Diluted) figures stand at -$5.11 (Q1 2026), $307.61 (Q4 2025), and -$121.63 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -5.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.11 |
| Dec 31, 2025 | 307.61 |
| Sep 30, 2025 | -121.63 |
| Jun 30, 2025 | -12.56 |
| Mar 31, 2025 | -5.21 |
| Dec 31, 2024 | -8.78 |
| Sep 30, 2024 | -8.05 |
| Jun 30, 2024 | -0.41 |
| Mar 31, 2024 | -0.45 |
| Dec 31, 2023 | -0.38 |
| Sep 30, 2023 | -0.49 |
| Jun 30, 2023 | -0.45 |
| Mar 31, 2023 | -0.43 |
| Dec 31, 2022 | -0.52 |
| Sep 30, 2022 | -0.63 |
| Jun 30, 2022 | -0.58 |
| Mar 31, 2022 | -0.61 |
| Dec 31, 2021 | -0.48 |
| Sep 30, 2021 | -0.50 |
| Jun 30, 2021 | -0.50 |